Kappa/Lambda light chains
EstablishedThe free light chain ratio is a core diagnostic and monitoring test for multiple myeloma and related plasma cell disorders.
This blood test measures two related proteins that plasma cells make. An abnormal balance between them is a strong sign of multiple myeloma or a related condition, and it's especially useful for tracking disease in patients whose cancer doesn't show up well on standard tests.
Free kappa and lambda light chains are unbound immunoglobulin fragments in blood; the ratio between them is a key diagnostic and monitoring tool for plasma cell disorders like multiple myeloma and light chain (AL) amyloidosis.
An abnormal free light chain ratio (outside roughly 0.26-1.65) indicates a clonal excess of one light chain type, supporting diagnosis of monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, or AL amyloidosis, and is essential for prognostication in virtually every plasma cell disorder.
Current IMWG guidelines make this one of three core tests (with serum protein electrophoresis and immunofixation) for diagnosing multiple myeloma; it is especially essential for monitoring "oligosecretory" or "non-secretory" myeloma and AL amyloidosis, where standard electrophoresis often misses disease activity that the free light chain ratio catches.
An involved/uninvolved free light chain ratio of 100 or greater (with the involved light chain at least 100 mg/L) is itself one of the defining biomarker criteria for active multiple myeloma requiring treatment, not just monitoring, under current IMWG diagnostic criteria.
Important interpretation caveat: kidney impairment raises both light chains together but usually preserves the ratio's reliability.
- IMWG. International Myeloma Working Group (IMWG) guidelines for serum free light chain analysis in multiple myeloma and related disorders.
- ARUP Consult. Kappa/Lambda Quantitative Free Light Chain With Ratio, Serum.